CLGN vs NVCR vs IDXX vs RGEN

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 43. 7x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IDEXX Laboratories, Inc.

(IDXX) is the cheapest at 43. 7x versus Repligen Corporation at 147. 0x. On forward P/E, IDEXX Laboratories, Inc. is actually cheaper at 38. 3x.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -97. 1% for CollPlant Biotechnologies Ltd. (CLGN). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus CLGN's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CollPlant Biotechnologies Ltd.

(CLGN) is the lower-risk stock at 0. 89β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 141% more volatile than CLGN relative to the S&P 500. On balance sheet safety, CollPlant Biotechnologies Ltd. (CLGN) carries a lower debt/equity ratio of 23% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -133. 9% for CollPlant Biotechnologies Ltd.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -32. 3% for CollPlant Biotechnologies Ltd. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -33. 5% for CLGN. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IDEXX Laboratories, Inc.

(IDXX) trades at 38. 3x forward P/E versus 64. 3x for Repligen Corporation — 26. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CLGN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; RGEN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.